 |
|
French drugs firm
Sanofi's logo is pictured inside the company's headquarters during the
company's 2014 annual results presentation in Paris February 5, 2015. Reuters/Charles
Platiau
|
Sanofi is teaming up with Germany’s Evotec and Austrian
biotech firm Apeiron Biologics to develop a new type of immune system-boosting
cancer medicine that could be given as tablets to fight both solid tumors and
blood cancers.
The French drugmaker said on Monday the tie up would focus on developing small
molecule-based immuno-oncology treatments, which could complement currently
available inhibitors.
NewsDaily report continues:
Under the collaboration,
Sanofi has the option of screening its own compound libraries to identify new
small-molecule candidates for development, it said in a statement.
The group will support
two years of research funding for Evotec and Apeiron and pay Evotec potentially
more than 200 million euros (US$219 million) if promising molecules are
identified.
The French group said it
would have sole responsibility for all development, regulatory, commercial and
manufacturing activities of the products.
Last week, Sanofi
announced a partnership with Evotec to develop stem cell-based treatments for
diabetes.
The company is also working
closely with its long-time partner Regeneron Pharmaceuticals in the area of
cancer immunotherapy.
No comments:
Post a Comment